IPSEN (OTCMKTS:IPSEY) Sets New 1-Year High – What’s Next?

IPSEN (OTCMKTS:IPSEY) shares reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $37.10 and last traded at $37.10, with a volume of 279 shares trading hands. The stock had previously closed at $35.32.

Analyst Ratings Changes

Separately, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of IPSEN in a research note on Monday, November 3rd. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat, IPSEN presently has an average rating of “Buy”.

IPSEN Stock Performance

The firm’s 50 day moving average is $34.39 and its 200 day moving average is $31.97.

About IPSEN

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.